Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinyouli timing trial for febrile neutropenia prevention in breast cancer chemotherapy
ChiCTR1800019516Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim in breast cancer (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Incidence of febrile neutropenia. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800019516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019516.